Findings show no reduction in clinical fracture among middle-aged, older men with hypogonadism<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Jan. 18, 2024 (HealthDay News) — Testosterone treatment does not result in a lower incidence of clinical fractures among middle-aged and older men with hypogonadism, according to a study published in the Jan. 18 issue of the New England Journal of Medicine<\/em>.<\/p>\n Peter J. Snyder, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues examined the risk for clinical fracture in a time-to-event analysis subtrial of a randomized placebo-controlled trial that evaluated the cardiovascular safety of testosterone treatment in middle-aged and older men with hypogonadism. Eligible men were aged 45 to 80 years with preexisting, or a high risk for, cardiovascular disease; one or more symptoms of hypogonadism; and two morning testosterone concentrations <300 ng\/dL in fasting plasma samples obtained at least 48 hours apart. A total of 5,204 participants were randomly assigned to apply testosterone or placebo gel daily (2,601 and 2,603, respectively).<\/p>\n The researchers found that a clinical fracture occurred in 3.50 and 2.46 percent of participants in the testosterone and placebo groups, respectively, after a median follow-up of 3.19 years (hazard ratio, 1.43). For all other fracture end points, the fracture incidence also seemed higher in the testosterone group.<\/p>\n “We did not expect these results, because most previous studies showed that testosterone improved many measures of bone structure and quality,” the authors write.<\/p>\n The study was funded by AbbVie, Acerus Pharmaceuticals, Endo Pharmaceuticals, and Upsher-Smith Laboratories.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n